Novo Nordisk faces off in court with South African weight-loss drug compounder
诺和诺德诺和诺德(US:NVO) Reuters·2026-06-10 18:16

公司法律行动 - 丹麦制药公司诺和诺德将于周三在南非法院提起诉讼，试图阻止未经批准的司美格鲁肽仿制药的销售[1] - 司美格鲁肽是其重磅减肥和糖尿病药物的关键成分[1] 产品与市场 - 司美格鲁肽是诺和诺德旗下畅销减肥药和糖尿病药的关键活性成分[1]

Novo Nordisk faces off in court with South African weight-loss drug compounder - Reportify